BARD C R INC (BCR)

US0673831097

331.24  -1.95 (-0.59%)

After market: 331.97 +0.73 (+0.22%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BARD C R INC

NYSE:BCR (12/28/2017, 7:18:13 PM)

After market: 331.97 +0.73 (+0.22%)

331.24

-1.95 (-0.59%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap24.14B
Shares
PE43.42
Fwd PE25.52
Dividend Yield0.24%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

BCR Daily chart

Company Profile

C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems etc.

Company Info

BARD C R INC

730 CENTRAL AVE

MURRAY HILL NJ 07974

P: 908-277-8000

CEO: Timothy M. Ring

BCR News

News Image3 years ago - Investor's Business DailyAmazon's Health Care Push Could Be Its Next Big Market Disruption

The growth of Amazon stock could be sustained for years if the company continues its foray into the health care industry, where it could be a disrupter.

News Image6 years ago - BD (Becton, Dickinson and Company)BD Completes Bard Acquisition, Creating New Global Health Care Leader
News Image6 years ago - S&P Dow Jones IndicesHuntington Ingalls Industries Set to Join S&P 500; Scientific Games to Join S&P MidCap 400 and Ultra Clean Holdings to Join S&P SmallCap 600
News Image6 years ago - BD (Becton, Dickinson and Company)BD Statement On MOFCOM Clearance Of Bard Acquisition
News Image6 years ago - BD (Becton, Dickinson and Company)BD Statement On FTC Clearance Of Bard Acquisition
News Image6 years ago - InvestorPlaceCR Bard (BCR) a Strong Buy on Exceptional Quant Score

Currently, CR Bard Inc (NYSE:BCR) has a Strong Buy using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BCR has had from Portfolio Grader for 3 months.

BCR Twits

Here you can normally see the latest stock twits on BCR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example